Eisai

News

NICE recommends Eisai's kidney cancer combination

NICE has recommended Eisai’s Kisplyx (lenvatinib) in combination with Novartis’ Afinitor (everolimus) in kidney cancer after the company further dropped its price.

News

3D Japan flag (with clipping path)see more country...

Eisai: UK gives pharma a poor deal, may invest elsewhere

Japanese pharma getting frustrated with NICE

News

NICE rejects Eisai's Halaven in new breast cancer use

NICE rejects drug after finding gap in clinical data

News

NICE rejects Bayer and Eisai drugs in thyroid cancer

Thyroid cancer drugs are available in Scotland and Wales

Views & Analysis

Medical Affairs – the heart of a data-driven, patient-centri...

Kirk Shepard, Eisai’s SVP of Global Medical Affairs Oncology, talks about how his profession has developed hugely in recent years, and how the new Medical Affairs Professional Society (MAPS) wi

News